73 search results for: expert insights

expert video

How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?

4 min

Dermatology

In this video soundbite from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson explains how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation.

expert video

KOL Video Interview – Dr. Eric Simpson

5 min

Dermatology

In this exclusive KOL interview, Dr. Eric Simpson explores the cumulative, long-term impact of atopic dermatitis and highlights the potential benefits of initiating treatment early to help manage disease burden.

expert video

Identifying BP: How do symptoms of BP and their severity alter patient diagnosis?

3 min

Dermatology

Dr. Victoria Werth explains how diagnosing BP can pose many difficulties in patients due to the variation of symptoms and symptom severity. Dr. Werth also discusses what burden and challenges BP patients might expect as a result.

expert video

Risk of Mortality and Infections in Bullous Pemphigoid

3 min

Dermatology

Dr. Victoria Werth walks through the serious comorbidity risks associated with BP diagnosis

expert video

The Impact of Type 2 Inflammation on the Neuroimmune Axis in AD

10 min

Dermatology

Dr. Gil Yosipovitch discussed the interaction between type 2 inflammation and itch in AD, the role of type 2 inflammation on neuroarchitecture, and the role of type 2 cytokines in neuronal sensitization.

expert video

A brief overview of the pathophysiology of PN

5 min

Dermatology

Dr. Chovatiya explains that PN is primarily a chronic itch disease with a complex pathophysiology involving neuronal changes, type 2 inflammation, and fibrotic skin processes, affecting patients' overall well-being.

expert video

Barrier disruption in AD and the development of environmental and food allergies

5 min

Dermatology

Dr. Casale discusses the critical role of barrier disruption in atopic dermatitis

expert video

What Is The COPD Vicious Cycle?

3 min

Pulmonology

Dr. Nicola Hanania explains the vicious cycle of exacerbations and lung function decline observed in COPD.

expert video

What proportion of patients can achieve control in CRSwNP?

5 min

Rhinology

Join Prof. Hellings and Prof. Corso in dicussion on the factors affecting complete control of CRSwNP, including treatment types, comorbidities, and the need for more data on biologics.

Podcast

ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

20 min

Dermatology

Professor Lisa Beck explores the chronic and persistent burden of atopic dermatitis (AD) as well as the concept of early intervention in patients with AD.

expert video

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

9 min

Rhinology

Dr. Stella Lee explores the past, present and future implementation of guidelines into daily practice

expert video

AD, PN, and CSU: Distinct, Pruritic Diseases

1 min

Dermatology

Dr. Elmariah explains how AD, PN, and CSU are distinct diseases with the common, burdensome symptom of itch.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: IsraelChange country/region